Novo Nordisk vs. Hims & Hers: The Lawsuit Changing Weight Loss Medicine

A major legal battle between Novo Nordisk and Hims & Hers could reshape the future of weight loss medicine — and directly impact patients using compounded GLP-1 medications. In this episode of Med Spa Confidential, Dr. Kate Dee breaks down the lawsuit over oral semaglutide, explains what Novo Nordisk is really asking the courts to do, and why the end of the FDA shortage loophole changes everything for compounding pharmacies. She also shares her clinical perspective on why tirzepatide may outperform semaglutide, and what emerging treatments like retatrutide could mean for the future of obesity care. If you're currently using compounded semaglutide — or considering starting a GLP-1 medication — this is essential listening before your next prescription.